Translational Development Acquisition (TDACU) Return on Equity (2024 - 2026)

Translational Development Acquisition has reported Return on Equity for 3 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 1.0% YoY), and the FY2025 full-year result was 0.01%, down 1.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.0% in Q4 2024, with the low at 0.01% in Q4 2025.
• Historically, Return on Equity has averaged 0.01% across 3 years, with a median of 0.01% in 2025.
• The largest YoY upside for Return on Equity was 1 bps in 2025 against a maximum downside of 1 bps in 2025.
• Translational Development Acquisition's Return on Equity stood at 0.0% in 2024, then plunged by 4293 bps to 0.01% in 2025, then increased by 6 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.